Cognitive & Mood
Dihexa
A synthetic angiotensin IV analog studied in the lab as a potent driver of synaptogenesis — the formation of new connections between neurons — via the HGF/c-Met pathway. Interest centers on memory and cognition, but the evidence is preclinical only: dihexa is not FDA approved, human safety data is very limited, and it's currently under FDA compounding review. Join the waitlist for California telehealth updates.
Coming soon
Get notified when Dihexa launches
Dihexaisn't available to prescribe just yet. Leave your email and we'll let you know the moment it's ready in California — no spam.
Physician-reviewed peptide therapy, prescribed only when appropriate.
Protocol at a glance
- Route
- Oral or subcutaneous
- Frequency
- Once daily
- Course
- Cyclical course
Physician-reviewed. Prescribed only if appropriate after a telehealth consult — full refund if a licensed clinician determines it isn't right for you.
Why patients choose it
Why researchers are interested in dihexa
Studied for synapse formation
In preclinical models, dihexa has been investigated for promoting synaptogenesis — building new synaptic connections — rather than simply stimulating existing pathways.
Acts on the HGF/c-Met pathway
Research describes its activity as potentiating hepatocyte growth factor (HGF) signaling through the c-Met receptor, a mechanism distinct from classic stimulant nootropics.
Designed to reach the brain
Dihexa was engineered with the intent of crossing the blood-brain barrier and remaining metabolically stable — features that make it a subject of cognitive research.
Overview
What dihexa is
Dihexa is a small synthetic peptide derived from angiotensin IV (a fragment of the angiotensin system). It was developed in academic research as a candidate for neurological conditions involving impaired synaptic connectivity:
- Mechanism (preclinical): potentiates HGF/c-Met signaling, which has been linked to synapse formation
- Research interest: memory, learning, and neuroprotection in cell and animal models
- Potency: reported in some lab assays to be markedly more active than reference neurotrophic factors — a research observation, not a human result
None of this has been confirmed in controlled human trials. Treat dihexa as experimental: the gap between a striking preclinical signal and a safe, effective human therapy is large, and it has not been bridged here.
Status
Regulatory & safety status
Where dihexa stands today:
- Not FDA approved for any indication
- Very limited human safety data; evidence is essentially preclinical (cell and animal studies)
- Under FDA compounding review — slated for the Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled before the end of February 2027, which will consider it for the Section 503A Bulk Drug Substances list
- PCAC recommendations are non-binding; rulemaking would still be required before anything changes
We are not selling dihexa today. Join the waitlist and we'll notify you only if a compliant, physician-supervised pathway becomes available. Any use would require direct medical supervision.
What to expect
How it unfolds, week by week
01
Now
Dihexa is investigational and not available to order. Joining the waitlist registers your interest and helps us gauge demand ahead of any regulatory change.
02
Before end of Feb 2027
The FDA's Pharmacy Compounding Advisory Committee is scheduled to review dihexa for the 503A bulk compounding list. The recommendation is advisory only.
03
If a pathway opens
Should compounding become permissible and clinically appropriate, we'd share physician-supervised details with waitlist members — never as an unsupervised product.
FAQ
Dihexa questions
Related peptides
Often explored together
Get notified about dihexa
Dihexa is investigational and under FDA compounding review. Join the waitlist and we'll reach out only if a compliant, physician-supervised pathway opens in California.
Join the WaitlistDihexa
Physician-reviewed